Skip to Content
Merck
All Photos(2)

Key Documents

More Documents

SBR00066

Sigma-Aldrich

Amikacin Ready Made Solution

25 mg/mL in water

Sign Into View Organizational & Contract Pricing
All Photos(2)

About This Item

CAS Number:
149022-22-0
UNSPSC Code:
51281632
NACRES:
NA.76

form

liquid

Quality Level

200

specific activity

Antibacterial

concentration

25 mg/mL in water

antibiotic activity spectrum

Gram-negative bacteria
Gram-positive bacteria
mycobacteria

Mode of action

protein synthesis | interferes

storage temp.

2-8°C

SMILES string

O=C([C@@H](O)CCN)N[C@H]1[C@H](O[C@@H]2[C@H](O)[C@@H](N)[C@H](O)[C@@H](CO)O2)[C@@H](O)[C@H](O[C@@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CN)O3)[C@@H](N)C1.O=S(O)(O)=O.[F,Cl,Br,I]

InChI

1S/C22H43N5O13.H2O4S/c23-2-1-8(29)20(36)27-7-3-6(25)18(39-22-16(34)15(33)13(31)9(4-24)37-22)17(35)19(7)40-21-14(32)11(26)12(30)10(5-28)38-21;1-5(2,3)4/h6-19,21-22,28-35H,1-5,23-26H2,(H,27,36);(H2,1,2,3,4)/t6-,7+,8-,9+,10+,11-,12+,13+,14+,15-,16+,17-,18+,19-,21+,22+;/m0./s1

InChI key

HIBICIOPDUTNRR-XTHCGPPUSA-N

General description

Amikacin is semisynthetic aminoglycoside antibiotic derived from kanamycin A. Amikacin has broad spectrum activity against serious gram-negative bacilli drug resistant infections and also mycobacteria type infections. Amikacin binds to 30S bacterial ribosomal subunit causing a change of conformation, thus disrupting mRNA’s interaction with tRNA and hampering bacterial growth. Amikacin also showed potency against some gram-positive bacteria like methicillin-resistant Staphylococcus aureus (MRSA). Amikacin is extensively used for multidrug resistant tuberculosis treatment with 1ug/mL MIC value against Mycobacterium tuberculosis. Additionally, Amikacin MIC studies of gram negative and gram positive bacteria showed MIC distribution range of 0.094-48µg/ml. Several other studies showed that Amikacin has a synergistic effect combined with β-lactams against methicillin-resistant Staphylococcus spp. strains and Pseudomonas aeruginosa. Amikacin is additionally used for wound healing assays at concentration of 250 µg/mL.

Other Notes

The suggested concentration of Amikacin for assays is 0.094-250 µg/mL therefore, it is recommended to dilute the ready made solution 1:100-266,000. Amikacin:Sulfate ratio 1:1.8

Pictograms

Exclamation mark
GHS07

Signal Word

Warning

Hazard Statements

H317

Hazard Classifications

Skin Sens. 1

Storage Class Code

12 - Non Combustible Liquids

WGK

WGK 1

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Etinosa O Igbinosa et al.
TheScientificWorldJournal, 2012, 308034-308034 (2012-05-26)
Pseudomonas aeruginosa is an opportunistic pathogen in environmental waters with a high prevalence of multidrug resistance. In this study the synergistic efficacy of synergy antibiotic combinations in multidrug-resistant P. aeruginosa strains isolated from an abattoir effluent was investigated. Water samples
N Düzgüneş et al.
Antimicrobial agents and chemotherapy, 32(9), 1404-1411 (1988-09-01)
We examined the therapeutic effects of free and liposome-encapsulated amikacin on Mycobacterium avium-M. intracellulare complex infection by using the beige-mouse model of the disease. In the first series of studies, intravenous administration of four weekly doses of 5 mg of
S Leitzke et al.
Antimicrobial agents and chemotherapy, 42(2), 459-461 (1998-04-04)
The potential of liposome-encapsulated antibiotics for prolonging drug application intervals was investigated by using a murine model of chronic lethal Mycobacterium avium infection. Liposomal encapsulation of amikacin, but not of ciprofloxacin, resulted in high and sustained drug levels in infected
Yun-Hsin Wang et al.
Toxics, 8(4) (2020-11-26)
(1) Background: Amikacin is an aminoglycoside antibiotic used for treating gram-negative bacterial infections in cancer patients. In this study, our aims are to investigate the migratory inhibition effects of amikacin in human MDA-MB-231 cells. (2) Methods: We used a wound-healing
Henri Sueke et al.
Investigative ophthalmology & visual science, 51(5), 2519-2524 (2009-12-19)
To determine the minimum inhibitory concentrations (MICs) of 12 antimicrobials in current ophthalmic use and 4 potentially new alternatives against isolates from bacterial keratitis. Bacteria were collected from cases of bacterial keratitis in six centers in the United Kingdom between
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service